胃食管反流病及质子泵抑制剂难治性症状的患病率
基于美国2015年全国胃肠调查(71,812人),44.1%曾出现胃食管反流病症状,30.9%过去一周有症状;每日服用质子泵抑制剂者中54.1%症状持续。年轻、女性、拉丁裔及合并肠易激综合征或克罗恩病者更易持续有症状。
要点
- 约2/5美国成人曾有胃食管反流病症状,1/3过去一周有症状。
- 每日服用质子泵抑制剂者中54.1%仍有持续反流症状。
- 年轻、女性、拉丁裔及合并肠易激综合征或克罗恩病者症状更易持续。
核心结论
- 胃食管反流病症状在美国人群中常见,且过半每日质子泵抑制剂使用者症状持续。
研究设计与样本
- 2015年全国胃肠调查,使用MyGiHealth应用引导参与者完成NIH胃肠患者报告结局测量信息系统调查,共71,812名参与者。
主要发现
- 71,812名参与者中32,878人(44.1%)报告曾出现胃食管反流病症状,23,039人(30.9%)报告过去一周有症状。
- 曾有症状者中35.1%目前在接受治疗,其中55.2%用质子泵抑制剂、24.3%用组胺2受体拮抗剂、24.4%用抗酸剂。
- 3,229名每日服用质子泵抑制剂者中54.1%有持续胃食管反流病症状。
关键数值与推荐
- 持续胃食管反流病症状定义为过去一周内烧心或反流≥2天。
临床怎么用
- 对每日质子泵抑制剂治疗仍有持续反流症状者,需识别难治性胃食管反流病并考虑进一步评估与治疗调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There are few data on the prevalence of gastroesophageal reflux disease (GERD) in the United States. We performed a population-based study to determine the prevalence of GERD symptoms and persistent GERD symptoms despite use of proton pump inhibitors (PPIs). METHODS: We conducted the National Gastrointestinal Survey in 2015 using MyGiHealth, an app that guides participants through National Institutes of Health gastrointestinal Patient-Reported Outcomes Measurement Information System surveys. Primary outcomes were prevalence of GERD symptoms in the past and persistence of GERD symptoms (heartburn or regurgitation 2 or more days in past week) among participants taking PPIs. Population weights were applied to the data and multivariable regression was used to adjust for confounding. RESULTS: Among 71,812 participants, 32,878 (44.1%) reported having had GERD symptoms in the past and 23,039 (30.9%) reported having GERD symptoms in the past week. We also found that 35.1% of those who had experienced GERD symptoms were currently on therapy (55.2% on PPIs, 24.3% on histamine-2 receptor blockers, and 24.4% on antacids). Among 3229 participants taking daily PPIs, 54.1% had persistent GERD symptoms. Younger individuals, women, Latino individuals, and participants with irritable bowel syndrome or Crohn's disease were more likely to have continued symptoms, even when taking PPIs. CONCLUSIONS: Using a population-based survey, we found GERD symptoms to be common: 2 of 5 participants have had GERD symptoms in the past and 1 of 3 had symptoms in the past week. We also found that half of PPI users have persistent symptoms. Given the significant effect of GERD on quality of life, further research and development of new therapies are needed for patients with PPI-refractory GERD symptoms.
引用
- Delshad SD, Almario CV, Chey WD, et al. Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. Gastroenterology. 2019. PMID: 31866243. doi:10.1053/j.gastro.2019.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。